Clinical Trial 20894

Acalabrutinib for Chronic Graft-versus-Host Disease

Disease Site: Unknown Sites

PI: Pidala, Joseph

Clinical Trial 21673

A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety ofHER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-Based Therapy (FLAMINGO-01)

Disease Site: Breast

PI: Soyano Muller, Aixa

Clinical Trial 90016

Disease Site: Other Hematopoietic

PI: Sandoval-Sus, Jose

Clinical Trial 20870

Pilot Study to Assess the Efficacy of Aspirin to Improve Immunological Features of Ovarian Tumors

Disease Site: Other Female Genital, Ovary

PI: Chern, Jing-Yi

Clinical Trial 20827

An Open-Label, Multi-Center Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T cells in Patients with Advanced Non-Small Cell Lung Cancer (CHIRON)

Disease Site: Lung, Non small cell lung cancer

PI: Creelan, Benjamin

Clinical Trial 20487

Phase I/II Study of Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Disease

Disease Site: Brain and Nervous System, Breast, Leptomeningeal (LMD)

PI: Ahmed, Kamran

Clinical Trial 20854

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Disease Site: Melanoma, skin, Other Skin

PI: Kanetsky, Peter

Clinical Trial 20274

A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA

Disease Site: Lip, Oral Cavity and Pharynx

PI: Kirtane, Kedar

Clinical Trial 21731

A Phase II Trial of Olaparib in Combination with Pembrolizumab for Advanced Uveal Melanoma

Disease Site: Melanoma, skin

PI: Khushalani, Nikhil

Clinical Trial 21559

Disease Site: Prostate

PI: Zhang, Jingsong

Clinical Trial 21117

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 Following ALLO-647 Containing Conditioning Regimen in Subjects with Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)

Disease Site: Kidney

PI: Chahoud, Jad

Clinical Trial 21247

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK)-Inhibitor

Disease Site: Myeloid and Monocytic Leukemia

PI: Komrokji, Rami